Update on the treatment of Chagas' disease;Estado actual en el tratamiento de la enfermedad de Chagas

Revista Medica de Chile

Volumn 139, Issue 2, 2011, Pages 247-257

  Werner Apt, B ^a   Ines Zulantay A ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Benzonidazole; Chagas cardiomyopathy; Chagas disease

Indexed keywords

ANTITRYPANOSOMAL AGENT;

ANIMAL; ARTICLE; CHAGAS DISEASE; CHRONIC DISEASE; HUMAN; PARASITOLOGY; TRYPANOSOMA CRUZI;

ANIMALS; CHAGAS DISEASE; CHRONIC DISEASE; HUMANS; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 79957631562     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: 10.4067/S0034-98872011000200016     Document Type: Article

References (48)

1. Aufderheide AC, Salo W, Madden M, Streitz J, Buikstra J, Guhl F, et al. 9000-year record of Chagas' disease. Proc Natl Acad Sci USA 2004; 101: 2034-9.
2. Apt W. [Treatment of Chagas disease]. Rev Med Chile 1985; 113: 162-6.
3. Pinto Dias J. Tratamiento etiológico de la enfermedad de Chagas. En XII Reunión de la Comisión Intergubernamental del Cono Sur para la eliminación de Triatoma infestans y la interrupción de la transmisión transfusional de la Tripanosomiasis Americana (INCOST/Chagas) 2004. pp 129-34. Washington DC. Pan American Health Organization.
4. Coura R. Chagas disease: clinical and therapeutic features. Enf Emerg 2005; 8: 18-24.
5. Steverding D, Tyler K. Novel antitrypanosomal agents. Expert Opin Investig Drugs 2005; 14: 939-55.
6. Andrade Z, Andrade S. Patología Da Doença de Chagas. En: Brener Z, Andrade Z, Barral-Neto M. (eds). Trypanosoma cruzi e doença de Chagas 2da. Edición. Río de Janeiro Guanabara Koogan 2000; 201-30.
7. Teixeira A, Nascimento R, Sturn N. Evolution and pathology in Chagas disease. A Review. Mem Inst Oswaldo Cruz 2006; 101: 463-91.
8. Brener Z. Terapéutica experimental na doença de Chagas. Trypanosoma cruzi e Doença de Chagas. Eds. Brener Z, Andrade Z. y Barral-Neto M, Guanabara Koogan. Rio de Janeiro 2000; 379-88.
9. Avila J, Avila A. Trypanosoma cruzi allopurinol in the treatment of mice with experimental acute Chagas disease. Exp Parasitol 1981; 51: 204-8.
10. Avila J, Avila A, Muñoz E, Monzon H. Trypanosoma cruzi: 4-aminopyrazolopyrimidine in the treatment of experimental Chagas disease. Exp Parasitol 1983; 56: 236-40.
11. Apt W, Arribada A, Zulantay I, Solari A, Sánchez G, Mundaca K, et al. Itraconazole and Allopurinol in the treatment of chronic American tripanosomiasis: the results of clinical and parasitological examinations 11 years post treatment. Ann Trop Med Parasitol 2005; 99: 733-41.
12. Tomimori-Yamashita J, Deps P, Almeida D, Enokihara M, De Seixas M, Freymuller E. Cutaneous manifestation of Chagas disease after heart transplantation: successful treatment with allopurinol. Br J Dermatol 1997; 137: 626-30.
13. Apt W, Aguilera X, Arribada A, Pérez C, Miranda C, Sánchez G, et al. Treatment of chronic Chagas disease with itraconazole and allopurinol. Am J Trop Med and Hyg 1998; 59: 133-8.
14. Urbina J. Chemotherapy of Chagas disease. Curr Pharm Des 2002; 8:287-95.
15. Zulantay I, Apt W, Gil L. C, Rocha C, Mundaca C, Solari A, et al. The PCR-based detection of Trypanosoma cruzi in the faeces of Triatoma infestans fed on patients with chronic American trypanosomiasis gives higher sensitivity and a quicker result than routine xenodiagnosis. Ann Trop Med Parasitol 2007; 101: 673-9.
16. Skies D, Vázquez J, Anstead G, Greybill J, Reynes J, Ward D, et al. Posaconazole for the treatment of azolerefractory oropharyngeal and esophaged candidiasis in subjects with HIV infection. Clin Infect Dis 2007; 44: 607-14.
17. Urbina J. New chemotherapeutic approaches for the treatment of Chagas disease (American Trypanosomiasis). Expert Opin Ther Patents 2003; 13: 661-9.
18. Maya J, Cassels B, Iturriaga-Vásquez P, Ferreira J, Faúndez M, Galanti N, et al. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physil 2006; 1-20.
19. Cazzulo J. Proteinases of Trypanosoma cruzi: patential targets for the chemotherapy of Chagas desease. Curr Top Med Chem 2002; 2: 1261-71.
20. Garzoni L, Waghabi M, Baptista M, de Castro S, Meirelles M, Britto C, et al. Antiparasitic activity of risedronate in a murine model of acute Chagas disease. Int J Antimicrob Agents 2004; 23: 286-90.
21. Hucke O, Gelb M, Verlinde C, Buckner F. The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem 2005; 48: 5415-8.
22. Lepesheva G, Zaitseva N, Nes W, Shou W, Arase M, Liu J, et al. CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B'helix define substrate preferences of sterol 14 alpha-demethylase. J Biol Chem 2006; 281: 3577-85.
23. Niemirowicz G, Parussini F, Aguero F, Cazzulo J. Two metallocarboxypeptidases from the protozoan Trypanosoma cruzi belong to the M32 family, found so far only in prokaryotes. Biochem J 2007; 401: 399-410.
24. Rawlings N. Unusual phyletic distribution of peptidases as a tool for identifying potential drug targets. Biochem J 2007; 401: 5-7.
25. Morello A, Lipchenca I, Cassels B, Speisky H, Aldunate J, Repetto Y. Trypanocidad effect of boldine and related alkaloids up on several strains of Trypanosoma cruzi. Comp Biochem Physiol 1994; 90: 1-12.
26. Tempone A, Borborema S, de Andrade H Jr, de Amorim N, Yogi A, Carvalho C, et al. Antiprotozoal activity of Brazilian plant extracts from isoquinoline alkaloidproducing families. Phytomedicine 2005; 12: 382-90.
27. Rubio J, Calderón J, Flores A, Castro C, Céspedes C. Trypanocidad activity of oleoresin and terpenoids isolated from Pinus oocarpa. Naturforsch 2005; 60: 711-6.
28. Uchiyama N, Kabututu Z, Kubata B, Kiuchi F, Ito M, Nakajima-Shimada J, et al. Antichagasic activity of komaroviquinone is due to generation of reactive oxygen species catalyzed by Trypanosoma cruzi old yellow enzyme. Antimicrob Agents Chemother 2005; 49: 5123-6.
29. Leite J, Oliveira A, Lombardi J, Filho J, Chiari E. Trypanocidal activity of triterpenes from Arrabidaea triplinervia and derivatives. Biol Pharm Bull 2006; 29: 2307-9.
30. De Oliveira C, Santana L, Carmona A, Cezari M, Sampaio M, Sampaio C, et al. Structure of cruzipain/cruzain inhibitors isolated from Bauhinia bauhinioides seeds. Biol Chem 2001; 382: 847-52.
31. Rassi A, Rassi Jr A, Rassi S. Cardiopatía crónica: arritmias. En Pinto Dias J. Coura J (eds). Doença de Chagas. Um manual para o clinico general. Río de Janeiro. Fio Cruz 1997; 201-22.
32. Prata A. Abordagem general do paciente chagasico. En Pinto Dias J. Coura (eds). Clinica e terapeutica do doença de Chagas. Um manual para o clinico general. Rio de Janeiro. Fio Cruz 1997; 115-26.
33. Pinto Dias J. The treatment of Chagas Disease (South American tripanosomiasis) Ann Int Med 2006; 144: 772-4.
34. Viotti R, Vigliano C, Lococo B, Álvarez M, Petti M, Bertochi G, et al. Side effects of benznidazole as treatment of Chagas disease: fears and realities. Expert Rev Anti Infect Ther 2009; 7: 157-63.
35. Apt W, Heitman I, Jercic MI, Jofré L, Muñoz P, et al. Guías clínicas de la enfermedad de Chagas. Parte VI. Tratamineto antiparasitario para enfermedad de Chagas. Rev Chil Infectol 2008; 25: 384-9.
36. Cerisola J. Evolución serológica de pacientes con enfermedad de Chagas aguda tratados con Bay 2502. Bol Chile Parasitol 1969; 24: 54-9.
37. Cançado R. Tratamiento etiológico do doença de Chagas pelo benznidazol. Capítulo 19. Libro Trypanosoma cruzi e doença de Chagas Eds. Brener Z, Andrade Z. y Barral-Neto M. Guanabara Koogan, Río de Janeiro 2000; 389-405.
38. Virreira M, Torrico F, Truyens C, Alonso-Vega C, Solano M, Carlier Y, et al. Comparison of polymerase chain reaction methods for reliable and easy detection of congenital Trypanosoma cruzi infection. Am J Trop Med Hyg 2003; 68: 574-82.
39. Sánchez O, Mora M., Basombrio M. High prevalence of congenital Trypanosoma cruzi infection and clustering in Salta, Argentina. Pediatrics 2005; 115: 668-72.
40. WHO. Control of Chagas disease. WHO Technical Report Series 2000; 905 Geneva.
41. Viotti R, Vigliano C, Lococo B, Bertocci G, Petti M, Álvarez M, et al. Long-term cardiac outcome of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006; 144: 724-34.
42. Bustamante J, Bixby L, Tarleton R. Drug induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med 2008; 14: 542-50.
43. Duffy T, Bisio M, Altcheh J, Burgos I, Díaz M, Levin M, et al. Accurate real-time PCR strategy for monitoring bloodstream parasites loads in Chagas disease patients. PLoS Negl Trop Dis 2009; 3: 419-29.
44. Britto C. Usefulness of PCR-based assays to assess drug efficacy in Chagas disease chemotherapy: value and limitations. Mem Inst Oswaldo Cruz 2009; 104: 122-35.
45. Marin-Neto JA, Rassi A Jr, Morillo CA, Avezum A, Connolly SJ, Sosa-Estani S, et al. BENEFIT Investigators. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the benznidazole evaluation for interrupting trypanosomiasis (BENEFIT) Am Heart J 2008; 156: 37-43.
46. Filardi L, Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans Roy Soc Trop Med Hyg 1987; 81:755-9.
47. Coronado X, Zulantay I, Rozas M, Apt W, Sánchez G, Rodríguez J, et al. Dissimilar distribution of Trypanosoma cruzi clones in humans alter chemotherapy with allopurinol and itraconazole. J Antimicrob Chemother 2006; 58: 216-9.
48. Rassi A Jr, Dias JC, Marín-Neto J, Rassi A. Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease. Heart 2009; 95: 524-34.